Table 7.

Published Studies Comparing the Distribution of Low-Affinity FcγR Genotypes in Disease Versus Normal Control Populations

FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  .066  .57 .062  22  36  11  18  50  27  Netherlands/CA Duits49 
SLE  .91  .87 .67  57  120  82  46  97  72  UK/CA Botto38 
SLE  .16  .12 .72  53  84  50  40  37  31  Germany/CA Manger40 
SLE  .61  .32 .69  12  38  16  10  49  22  Greece/CA Smyth50 
SLE  .30  .61 .12  20  24  8  14  16  12  USA/CA Smyth50 
SLE  .48  .50 .24  24  44  19  16  33  21  Netherland-USA/CA Koene61 
SLE  .13  .062f .34  11  30  15  5  38  23  USA/CA  Salmon (a)53 
SLE  .23  .086 .68  17  35  25  8  37  25  Caribbean/AA Botto38 
SLE  .015  .0065f .26  14  15  10  4  23  16  USA/AA Salmon58 
SLE  .021  .047 .011  27  50  23  37  97  80  USA/AA Salmon58 
SLE  .61  .33 1.00f  24  20  5  18  23  5  China/PR Botto38 
SLE  .0041  .0009 .41f  22  37  5  8  56  9  Korea/PR Song60 
Subtotal:  .078  .14  199 376  201  149  320  208  CA  
SLE  .085  
 .001  .0007  58  100  58  49 157  121  AA  
  .014  
 .008  .0019 46  57  10  26  79  14  PR  
  .47 
 <.0001  <.0001  303  533  269  224  556 343  Total  
  .0022         
HIT  .044  .015 .15  19  49  32  33  41  22  USA/ED Brandt45 
HIT  .022  .39f .0098f  2  13  7  4  15  0  Australia/CA Burgess57 
HIT  .065  .022 .19  61  124  79  30  35  19  Canada/ED Denomme47 
HIT  .20  .18f .79f  75  99  44  5  16  4  France/CA Bachelot-Loza39 
HIT  .90  1.00f 1.00f  20  56  26  2  8  3  USA/CA Arepally44 
HIT  .0008  .0003 .019  182  300  125  77  207  105  Germany/CA Carlsson66 
Subtotal:  .31  .13  359 641  313  151  322  153  Total  
HIT  .82          
ITP, refractory .009  .16f .0028  15  35  11  3  12  14  Ireland/CA Williams51 
ITP  .50  .31 .44f  26  52  22  10  14  4  Canada/ED Horsewood (a)46 
Subtotal:  .23  .69 41  87  33  13  26  18  Total  
ITP  .089         
 
Thrombosis anticardiolipin antibody  ND  .053 ND  25  78RR+HR 18 27RR+HR USA/CA  Salmon (a)63 
Antiphospholipid syndrome  .79  .94 .50  9  22  9  21  48  27  UK/CA  Caliz (a)55 
Wegener's granulomatosis  .47  .22 .71  38  79  32  47  71  29  USA/CA Edberg41 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  .066  .57 .062  22  36  11  18  50  27  Netherlands/CA Duits49 
SLE  .91  .87 .67  57  120  82  46  97  72  UK/CA Botto38 
SLE  .16  .12 .72  53  84  50  40  37  31  Germany/CA Manger40 
SLE  .61  .32 .69  12  38  16  10  49  22  Greece/CA Smyth50 
SLE  .30  .61 .12  20  24  8  14  16  12  USA/CA Smyth50 
SLE  .48  .50 .24  24  44  19  16  33  21  Netherland-USA/CA Koene61 
SLE  .13  .062f .34  11  30  15  5  38  23  USA/CA  Salmon (a)53 
SLE  .23  .086 .68  17  35  25  8  37  25  Caribbean/AA Botto38 
SLE  .015  .0065f .26  14  15  10  4  23  16  USA/AA Salmon58 
SLE  .021  .047 .011  27  50  23  37  97  80  USA/AA Salmon58 
SLE  .61  .33 1.00f  24  20  5  18  23  5  China/PR Botto38 
SLE  .0041  .0009 .41f  22  37  5  8  56  9  Korea/PR Song60 
Subtotal:  .078  .14  199 376  201  149  320  208  CA  
SLE  .085  
 .001  .0007  58  100  58  49 157  121  AA  
  .014  
 .008  .0019 46  57  10  26  79  14  PR  
  .47 
 <.0001  <.0001  303  533  269  224  556 343  Total  
  .0022         
HIT  .044  .015 .15  19  49  32  33  41  22  USA/ED Brandt45 
HIT  .022  .39f .0098f  2  13  7  4  15  0  Australia/CA Burgess57 
HIT  .065  .022 .19  61  124  79  30  35  19  Canada/ED Denomme47 
HIT  .20  .18f .79f  75  99  44  5  16  4  France/CA Bachelot-Loza39 
HIT  .90  1.00f 1.00f  20  56  26  2  8  3  USA/CA Arepally44 
HIT  .0008  .0003 .019  182  300  125  77  207  105  Germany/CA Carlsson66 
Subtotal:  .31  .13  359 641  313  151  322  153  Total  
HIT  .82          
ITP, refractory .009  .16f .0028  15  35  11  3  12  14  Ireland/CA Williams51 
ITP  .50  .31 .44f  26  52  22  10  14  4  Canada/ED Horsewood (a)46 
Subtotal:  .23  .69 41  87  33  13  26  18  Total  
ITP  .089         
 
Thrombosis anticardiolipin antibody  ND  .053 ND  25  78RR+HR 18 27RR+HR USA/CA  Salmon (a)63 
Antiphospholipid syndrome  .79  .94 .50  9  22  9  21  48  27  UK/CA  Caliz (a)55 
Wegener's granulomatosis  .47  .22 .71  38  79  32  47  71  29  USA/CA Edberg41 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
Myasthenia gravis  .12  .13 .054  9  18  22  10  13  7  Norway/CA Raknes32 
Periodontitis  .71  .56 .53f  63  38  4  56  38  6  Japan/PR Kobayashi31 
Meningococcal disease  .058 .81 .021  307-150 587-150 197-150 26  41  31 Russia/CA  Platonov64 
Meningococcal disease, Age >5  .022  .32 .0056  307-150 587-150 197-150 11  22  20 Russia/CA  Platonov64 
Sickle cell + S pneumoniae, .41  .22 .87  77-150 307-150 137-150 12  25  14 USA/AA  Norris59 
Sickle cell + H influenzae, .002  .0004 .43  77-150 307-150 137-150 7  3  1 USA/AA  Norris59 
Recurrent bacterial respiratory infections  .067  .022 .25  36  59  28  6  27  15  Netherlands/CA Sanders42 
FcγRIIIa
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; FF, VF, VV)  Control Genotype Case Genotype Country/ Ethnic Group  Reference 
FF  VF VV  FF  VF  VV  
SLE  .004  .009 .016 .19  28  44  15  41  22  7  Netherlands/ USA/CA Koene61 
SLE  .0072  .0017 .013 .46  29  69  15  87  92  21  USA/CA Wu24 
Subtotal:  .003  <.0001  57 113  30  128  114  28  
SLE   .0015 
  .21         
FcγRIIIb
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; 1/1, 1/2, 2/2) Control Genotype Case Genotype Country/ Ethnic Group  Reference  
1/17-152 1/2  2/2  1/1 1/2  2/2  
Myasthenia gravis  .7096  .47f .54 .86  4  28  17  4  15  11  Norway/CA Raknes32 
SLE  .78  .58 .54 .82  11  39  37  11  28  31  Netherlands USA/CA Koene61 
Recurrent bacterial respiratory infections  .09027-151 .0297-151 .32 .68  None  10  19  19  Netherlands/CA Saunders42 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
Myasthenia gravis  .12  .13 .054  9  18  22  10  13  7  Norway/CA Raknes32 
Periodontitis  .71  .56 .53f  63  38  4  56  38  6  Japan/PR Kobayashi31 
Meningococcal disease  .058 .81 .021  307-150 587-150 197-150 26  41  31 Russia/CA  Platonov64 
Meningococcal disease, Age >5  .022  .32 .0056  307-150 587-150 197-150 11  22  20 Russia/CA  Platonov64 
Sickle cell + S pneumoniae, .41  .22 .87  77-150 307-150 137-150 12  25  14 USA/AA  Norris59 
Sickle cell + H influenzae, .002  .0004 .43  77-150 307-150 137-150 7  3  1 USA/AA  Norris59 
Recurrent bacterial respiratory infections  .067  .022 .25  36  59  28  6  27  15  Netherlands/CA Sanders42 
FcγRIIIa
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; FF, VF, VV)  Control Genotype Case Genotype Country/ Ethnic Group  Reference 
FF  VF VV  FF  VF  VV  
SLE  .004  .009 .016 .19  28  44  15  41  22  7  Netherlands/ USA/CA Koene61 
SLE  .0072  .0017 .013 .46  29  69  15  87  92  21  USA/CA Wu24 
Subtotal:  .003  <.0001  57 113  30  128  114  28  
SLE   .0015 
  .21         
FcγRIIIb
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; 1/1, 1/2, 2/2) Control Genotype Case Genotype Country/ Ethnic Group  Reference  
1/17-152 1/2  2/2  1/1 1/2  2/2  
Myasthenia gravis  .7096  .47f .54 .86  4  28  17  4  15  11  Norway/CA Raknes32 
SLE  .78  .58 .54 .82  11  39  37  11  28  31  Netherlands USA/CA Koene61 
Recurrent bacterial respiratory infections  .09027-151 .0297-151 .32 .68  None  10  19  19  Netherlands/CA Saunders42 

Table 7 includes published studies in which the raw numbers were available for recalculation. Studies listed more than once and report distinct populations in the paper are treated as separate populations for the purpose of the analysis. Analysis of individual studies and subtotals of comparable studies were analyzed by χ2 3 × 2 test (with 2 degrees of freedom) for overall significance and also by χ2 2 × 2 test (with 1 degree of freedom) for each genotype, when relevant. Raw values are presented and not corrected in the table. Thus, values may differ from the published data because of correction factors determined by the investigators. In selected studies in which there were too few measurements in a cell, the Fischer exact test was performed and is indicated by an f. The following symbols indicate ethnic background: CA, Caucasians (North American or European); AA, African Americans; PR, Pacific Rim; ED, ethnically diverse.

Abbreviations: SLE, systemic lupus erythematosus; HIT, heparin induced thrombocytopenia; ITP, idiopathic thrombocytopenia purpura.

F7-150

Indicates a control population used for multiple comparisons; however, the numbers were included only once in the sum for the meta-analysis.

F7-151

Comparison made with our Caucasian control population.

F7-152

In the table, 1 = NA1 and 2 = NA2.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal